Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design

Source The Motley Fool

Recursion Pharmaceuticals (NASDAQ:RXRX), an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Trading volume reached 39.4M shares, coming in about 65% above its three-month average of 23.8M shares. Recursion Pharmaceuticals IPO'd in 2021 and has fallen 91% since going public.

How the markets moved today

S&P 500 (SNPINDEX:^GSPC) closed at 7,323, down 0.24%, while Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 24,430, up 0.42%. In biotechnology: AI-enabled drug discovery and clinical-stage therapeutics, Schrödinger (NASDAQ:SDGR) closed at $27.20, up 6.00%, and Relay Therapeutics (NASDAQ:RLAY) closed at $16.51, up 0.24%.

What this means for investors

Recursion shares are up 4% today after it aligned with the FDA on a Phase III trial design for 200 adults with familial adenomatous polyposis. The disease currently has no approved therapies, making Recursion's REC-4881 one of the first AI-enabled treatments to advance toward a Phase III trial.

Recursion believes there are over 50,000 patients with familial adenomatous polyposis in the U.S. and E.U., representing a $15 billion market opportunity for the $1.7 billion company. The FDA accepted 10 mm or larger polyp excision as part of its primary endpoint of event-free survival, which could be a win for RXRX stock, as it shouldn't have to run a longer, costlier trial waiting for adverse events to develop further.

While today's development is great progress for the stock, the results of the Phase III trial itself remain paramount, as success with REC-4881 would serve as a proof of concept not just for Recursion but for its AI platform. The Phase III trial won't begin until the second half of 2027, however, so interested investors need to be uber-patient and risk-tolerant before considering this stock.

Should you buy stock in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Schrödinger. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
12 hours ago
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
Author  TradingKey
14 hours ago
Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
19 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
Author  FXStreet
21 hours ago
The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
Yesterday 09: 10
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
goTop
quote